Skip to Content
Search Menu

DESTINY-Breast11 and Neoadjuvant T-DXd: Insights from Finland

Interview: The results of DESTINY-Breast11 for neoadjuvant T-DXd, either as monotherapy or followed by paclitaxel-trastuzumab-pertuzumab (THP), do not directly reflect Finnish clinical practice, says Maria Sundvall, Consultant Medical Oncologist at Turku University Hospital.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Related

Emerging Treatment for High-Risk HER2-Positive Early Breast Cancer — A new therapeutic option for the primary refractory patients 

/ Jan Andreasen
Breast cancerESMO25

SABCS 2025: Favorable Benefit–Risk Profile of Sacituzumab Govitecan in Previously Untreated Metastatic TNBC PD-L1–ineligible Metastatic Triple-Negative Breast Cancer

/ Jan Andreasen
Breast cancerNBCNSABCS25
Kirsten Marie Woolpert

SABCS 2025: Patterns of Opioid Use Among Breast Cancer Survivors

/ Kirsten Marie Woolpert
Breast cancerNBCNSABCS25 Play the Video 4:41
Sandra Jensen

Metastatic Deposit Size as a Predictor of Axillary Disease After Neoadjuvant Chemotherapy

/ Sandra Jensen
Breast cancerNBCN Play the Video 5:52

Significant therapeutic advancement for patients with HER2-positive biliary tract cancer

/ Jan Andreasen
ESMO25NBCN
Teresa Macarulla

ESMO 2025: HER2-Targeted Therapy Advances in BTC

/ Teresa Macarulla
ESMO25NBCN Play the Video 4:06

Sustained efficacy and quality of life with darolutamide + ADT in mHSPC patients of all ages

/ Jan Andreasen
ESMO25Prostate cancer

RNA Expression Profiles May Guide Future Targeted Therapy in Urothelial Cancer

/ Jan Andreasen
Bladder cancerESMO25
Peeter Karihtala

The Clinical Value of Immuno-Oncological Treatments in Early Breast Cancer

/ Peeter Karihtala
Breast cancerNBCNOnkologiapäivät 2025 Play the Video 09:38
Back to top